Retirement Systems of Alabama Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Retirement Systems of Alabama boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 998,307 shares of the biopharmaceutical company's stock after purchasing an additional 236,453 shares during the quarter. Retirement Systems of Alabama owned about 0.08% of Gilead Sciences worth $92,214,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of GILD. nVerses Capital LLC purchased a new position in Gilead Sciences during the 3rd quarter worth $25,000. HHM Wealth Advisors LLC boosted its holdings in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares during the last quarter. Valued Wealth Advisors LLC boosted its holdings in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 161 shares during the last quarter. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the 4th quarter worth $29,000. Finally, Crews Bank & Trust purchased a new position in Gilead Sciences during the 4th quarter worth $31,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of GILD stock traded down $2.00 during trading on Friday, hitting $96.04. The company had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock's 50-day moving average is $93.04 and its two-hundred day moving average is $86.65. The stock has a market capitalization of $119.69 billion, a price-to-earnings ratio of 1,067.11, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $100.51.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.29 earnings per share. As a group, analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GILD. Mizuho lifted their price objective on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Barclays boosted their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the stock an "equal weight" rating in a report on Thursday, November 7th. Truist Financial boosted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a report on Friday, November 8th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $84.00 price target on shares of Gilead Sciences in a report on Monday, February 3rd. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.